Vinflunine : A New Microtubule Inhibitor Agent : The development of new cytotoxic agents in clinical oncologyBENNOUNA, Jaafar; DELORD, Jean-Pierre; CAMPONE, Mario et al.Clinical cancer research. 2008, Vol 14, Num 6, pp 1625-1632, issn 1078-0432, 8 p.Article

Pharmacokinetics, Metabolites, and Preclinical Safety of VinflunineLOBERT, Sharon; PUOZZO, Christian.Seminars in oncology. 2008, Vol 35, Num 3, issn 0093-7754, S28-S33, SUP3Article

Antitumor Activity of Vinflunine : Effector Pathways and Potential for SynergiesBRAGUER, Diane; BARRET, Jean-Marc; MCDAID, Hayley et al.Seminars in oncology. 2008, Vol 35, Num 3, issn 0093-7754, S13-S21, SUP3Article

Vinflunine : Discovery and Synthesis of a Novel Microtubule InhibitorFAHY, Jacques; HELLIER, Paul; BREILLOUT, Fabienne et al.Seminars in oncology. 2008, Vol 35, Num 3, issn 0093-7754, S3-S5, SUP3Article

Pharmacokinetics, tissue distribution and excretion of vinflunineZHAO, Xiao-Ping; LIU, Xiao-Quan; WANG, Yong-Sheng et al.European journal of drug metabolism and pharmacokinetics. 2006, Vol 31, Num 2, pp 59-64, issn 0378-7966, 6 p.Article

Exploring the Mechanisms of Action of the Novel Microtubule Inhibitor VinflunineJORDAN, Mary Ann; BAND HORWITZ, Susan; LOBERT, Sharon et al.Seminars in oncology. 2008, Vol 35, Num 3, issn 0093-7754, S6-S12, SUP3Article

Development of a sensitive liquid chromatography method coupled with a tandem mass spectrometric detection for the clinical analysis of vinflunine and 4-O-deacetyl vinflunine in blood, urine and faecesZORZA, G; VAN HEUGEN, J. C; DE GRAEVE, J et al.Journal of chromatography. B. 2007, Vol 853, Num 1-2, pp 294-302, issn 1570-0232, 9 p.Article

Further mechanistic unravelling of the influence of the cell cycle effects on the radiosensitising mechanism of vinflunine, in vitroSIMOENS, Cindy; PAUWELS, Bea; VERMORKEN, Jan B et al.Cancer chemotherapy and pharmacology. 2008, Vol 62, Num 2, pp 183-193, issn 0344-5704, 11 p.Article

Cell cycle effects of vinflunine, the most recent promising Vinca alkaloid, and its interaction with radiation, in vitroSIMOENS, Cindy; VERMORKEN, Jan B; KORST, Annelies E. C et al.Cancer chemotherapy and pharmacology. 2006, Vol 58, Num 2, pp 210-218, issn 0344-5704, 9 p.Article

Update on tubulin-binding agents : Stem cellsATTARD, Gerhardt; GREYSTOKE, Alastair; KAYE, Stan et al.Pathologie et biologie. 2006, Vol 54, Num 2, pp 72-84, issn 0369-8114, 13 p.Article

Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunctionDELORD, J. P; RAVAUD, A; BENNOUNA, J et al.Investigational new drugs. 2013, Vol 31, Num 3, pp 724-733, issn 0167-6997, 10 p.Article

A Simple and Sensitive High-Performance Liquid Chromatographic Method for the Determination of Vinflunine and 4-O-Deacetylvinflunine From Human BloodZORZA, Grégoire; PELLERIN, Delphine; FORTUNE, Valérie et al.Therapeutic drug monitoring. 2010, Vol 32, Num 6, pp 734-740, issn 0163-4356, 7 p.Article

Clinical Activity of Vinflunine in Transitional Cell Carcinoma of the Urothelium and Other Solid TumorsBELLMUNT, Joaquim; DELGADO, Francois-Michel; GEORGE, Claude et al.Seminars in oncology. 2008, Vol 35, Num 3, issn 0093-7754, S34-S43, SUP3Article

Antiangiogenic concentrations of vinflunine increase the interphase microtubule dynamics and decrease the motility of endothelial cellsPOURROY, Bertrand; HONORE, Stéphane; PASQUIER, Eddy et al.Cancer research (Baltimore). 2006, Vol 66, Num 6, pp 3256-3263, issn 0008-5472, 8 p.Article

New agents for treatment of advanced transitional cell carcinomaPERABO, F. G. E; MÜLLER, S. C.Annals of oncology. 2007, Vol 18, Num 5, pp 835-843, issn 0923-7534, 9 p.Article

Head and neck carcinoma cell lines are sensitive to vinflunine in vitroERJALA, Kaisa; RAITANEN, Misa; KULMALA, Jarmo et al.Anticancer research. 2005, Vol 25, Num 6B, pp 4363-4367, issn 0250-7005, 5 p.Article

Hyponatrémie sévère chez un patient atteint d'un carcinome urothélial traité par chimiothérapieHEIBLIG, M; PICARD, C; GENESTE, M. A et al.JOG, le journal d'oncogériatrie. 2012, Vol 3, Num 5, pp 233-236, issn 2106-8534, 4 p.Article

Phase I dose-escalation study of oral vinflunine administered once daily for 6 weeks every 8 weeks in patients with advanced/metastatic solid tumoursDELORD, J. P; TOURANI, J. M; LEFRESNE, F et al.Cancer chemotherapy and pharmacology. 2013, Vol 71, Num 3, pp 647-656, issn 0344-5704, 10 p.Article

Phase II study of IV vinflunine in patients with chemotherapy naive metastatic malignant melanomaOLVER, I. N; BYRNE, M. J; WALPOLE, E et al.European journal of cancer (1990). 2007, Vol 43, Num 12, pp 1829-1832, issn 0959-8049, 4 p.Article

Phase I dose-escalation study of vinflunine hard capsules administered twice a day for 2 consecutive days every week in patients with advanced/metastatic solid tumorsCALVO, E; VERMORKEN, J. B; BENNOUNA, J et al.Cancer chemotherapy and pharmacology. 2012, Vol 69, Num 6, pp 1467-1475, issn 0344-5704, 9 p.Article

Impact actuel des produits naturels sur la découverte de nouveaux médicaments anticancéreux = Current impact of natural products in the discovery of anticancer drugsMONNERET, C.Annales pharmaceutiques françaises. 2010, Vol 68, Num 4, pp 218-232, issn 0003-4509, 15 p.Conference Paper

Determination of vinflunine in rat plasma by liquid chromatography- : electrospray ionization mass spectrometry for a pharmacokinetic studyXIAOPING ZHAO; XIAOQUAN LIU; YONGSHENG WANG et al.Journal of pharmaceutical and biomedical analysis. 2006, Vol 41, Num 3, pp 906-911, issn 0731-7085, 6 p.Article

La vinflunine, nouvel agent anticancéreux fluoré dérivé des alcaloïdes de Vinca = Vinflunine: a new anti-cancer fluorinated agent derived from vinca-alkaloïdsJACQUESY, J. C; JOUANNETAUD, M. P.Annales pharmaceutiques françaises. 2005, Vol 63, Num 1, pp 28-34, issn 0003-4509, 7 p.Article

A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimenCULINE, S; THEODORE, C; DE SANTIS, M et al.British journal of cancer. 2006, Vol 94, Num 10, pp 1395-1401, issn 0007-0920, 7 p.Article

A phase I clinical and pharmacokinetic study evaluating vinflunine in combination with epirubicin as first-line treatment in metastatic breast cancerCHAN, S; CAMPONE, M; SANTORO, A et al.Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 5, pp 903-910, issn 0344-5704, 8 p.Article